PHOENIX, AZ – 04-05-2018 (Press Release Jet) — Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that Timothy Henry MD has joined the Scientific Advisory Board.
Dr. Henry, an expert known for his innovative work in developing stem cell treatments for advanced heart disease patients is an interventional cardiologist and the Director of Cardiology at Cedars Sinai Heart Institute in Los Angeles.
Dr. Henry has authored over 400 studies published in peer-reviewed medical journals. He currently serves as the chairman of the Acute Coronary Syndrome Committee for the AHA Mission: Lifeline Program, the AHA Acute Cardiac Care Committee of the Council on Clinical Cardiology and Executive Committee of the Society for Cardiovascular Angiography and Interventions. He has served as national principal investigator of multiple large, multicenter trials in acute coronary syndromes, myocardial infarction and refractory angina including several ongoing cardiovascular stem cell trials, including RENEW, ALLSTAR and ATHENA. He is also principal investigator for one of seven NIH Clinical Cardiovascular Stem Cell Centers. As a visiting professor, Henry has lectured throughout the world on systems of care for acute myocardial infarction, refractory angina and stem cell therapy for cardiovascular disease.
“I have worked with Dr. Henry for many years in the development of advanced stem cell technology and his vast experience is a great compliment to our existing board” said Amit Patel MD MS, founder and Director of Creative Medical Technology Holdings, Inc.
“We are excited that Dr. Henry has agreed to join our Scientific Advisory Board and for the wealth of knowledge and experience he will bring in further advancing our existing technology and our continued development of cutting edge stem cell technology for the treatment of unmet patient needs for multiple indications in a responsible and ethical manner” said Timothy Warbington, Chairman and CEO of Creative Medical Technology Holdings.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
For the original news story, please visit https://pressreleasejet.com/news/stem-cell-clinical-trial-expert-to-join-scientific-advisory-board.html.
Latest posts by Brad Bennett (see all)
- HELLAS PROMOTES HARPER SEATON TO DFW BUSINESS DEVELOPMENT DIRECTOR - November 13, 2018
- Fintech Marketing Agency Releases Playbook Designed to Improve Marketing ROI - November 13, 2018
- Former DST executive, Nick Horvath, to join M3Sixty - November 13, 2018